BioGend Therapeutics Co., Ltd.(TW:6733)
NT$21.00+0.15 (+0.72%)
TW:6733
BioGend Therapeutics Co., Ltd. Revenue
NT$21.00
At close:+0.15 (+0.72%)
BioGend Therapeutics Co., Ltd. (6733) Revenue
BioGend Therapeutics Co., Ltd. Revenue
BioGend Therapeutics Co., Ltd. had a revenue of 59.49M in the quarter ending Jun 30, 2026, with 8.27%. This bring the company's revenue in the last twelve months to 236.58M, Increased 2.95%. In the fiscal year ending Dec 31, 2025, BioGend Therapeutics Co., Ltd. had annual revenue of 222.34M with 32.62% growth.
- Revenue (ttm)
- 236.58M
- Revenue Growth
- 10.74%
- P/S Ratio
- 12.60
- Revenue/Employee
- TWD 6,539,324
- Employees
- 34
- Market Cap
- TWD 2.80B
Revenue Chart
BioGend Therapeutics Co., Ltd. Revenue - Annual
Revenue History
| Fiscal End Date | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 222.34M | 54.69M | 32.62% |
| Dec 31, 2024 | 167.65M | 57.74M | 52.53% |
| Dec 31, 2023 | 109.91M | 78.46M | 249.51% |
| Dec 31, 2022 | 31.45M | 22.18M | 239.26% |
| Dec 31, 2021 | 9.27M | 7.88M | 565.40% |
| Dec 31, 2020 | 1.39M | -68.00K | -4.65% |
| Dec 31, 2019 | 1.46M | ― | ― |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.